← ANALYST RATINGS · TIPRANKS
TransMedics Group (TMDX): analyst forecast and price target
Analyst consensus
Moderate Buy6 Buy3 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $100, the highest $122, the lowest $65.00. The average is +41.3% from the last price of $70.78.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $95.00 → $79.00−16.8% | Buy | +11.6% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $92.00 → $77.00−16.3% | Hold | +8.8% | Downgrade | 17.10.26on TipRanks 04:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $92.00 → $76.00−17.4% | Hold | +7.4% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $91.00 → $76.00−16.5% | Hold | +7.4% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $96.00 → $80.00−16.7% | Buy | +13.0% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $96.00 → $80.00−16.7% | Buy | +13.0% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| Thomas Stephan★★★★★★★★★★#3049 · hits 47% · avg +8.4% | Stifel Nicolaus | $65.00 | Hold | −8.2% | Reiterated | 15.10.26on TipRanks 10:26 | +1.0%next day −6.4% | ↗ |
| William Plovanic★★★★★★★★★★#5377 · hits 43% · avg +1.3% | Canaccord Genuity | $95.00 → $94.00−1.1% | Buy | +32.8% | Reiterated | 13.10.26on TipRanks 07:10 | +1.2%next day −3.5% | ↗ |
| Christopher Pasquale★★★★★★★★★★#1776 · hits 61% · avg +11.9% | Nephron | $120 | Buy | +69.5% | Initiated | 06.10.26on TipRanks Oct 7 05:20 | −3.8%next day +1.2% · 5 days −1.3% | ↗ |
| Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% | Piper Sandler | $100 | Buy | +41.3% | Reiterated | 05.10.26on TipRanks 07:56 | +3.3%next day −3.8% · 5 days −6.2% | ↗ |
| Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% | TD Cowen | $120 | Buy | +69.5% | Reiterated | 02.10.26on TipRanks 08:30 | +0.7%next day +3.3% · 5 days −3.6% | ↗ |
| Ryan Daniels★★★★★★★★★★#2878 · hits 48% · avg +5.8% | William Blair | — | Buy | — | Reiterated | 02.10.26on TipRanks 05:15 | +0.7%next day +3.3% · 5 days −3.6% | ↗ |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | $106 | Buy | +49.8% | Assigned | 22.09.26on TipRanks 05:45 | +0.9%next day −0.5% · 5 days −3.4% | ↗ |
| Suraj Kalia★★★★★★★★★★#1646 · hits 50% · avg +6.8% | Oppenheimer | — | Hold | — | Reiterated | 24.08.26on TipRanks 10:13 | −0.9%next day −0.3% · 5 days −9.8% | ↗ |
| Allen Gong★★★★★★★★★★#2251 · hits 46% · avg +14.7% | J.P. Morgan | $73.00 | Hold | +3.1% | Reiterated | 06.08.26on TipRanks Aug 7 08:10 | +5.0%next day +4.0% · 5 days +10.5% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $80.00 → $77.00−3.7% | Hold | +8.8% | Assigned | 05.08.26on TipRanks 09:10 | −5.1%next day +5.0% · 5 days +13.4% | ↗ |
| David Rescott★★★★★★★★★★#3448 · hits 49% · avg +5.1% | Robert W. Baird | $120 → $122+1.7% | Buy | +72.4% | Reiterated | 05.08.26on TipRanks 07:45 | −5.1%next day +5.0% · 5 days +13.4% | ↗ |
| Daniel Markowitz CFA★★★★★★★★★★#1752 · hits 61% · avg +22.3% | Evercore ISI | $100 → $90.00−10.0% | Buy | +27.2% | Reiterated | 06.07.26on TipRanks 08:55 | +2.6%next day +0.3% · 5 days +6.6% | ↗ |
| Young Li★★★★★★★★★★#12189 · hits 16% · avg −26.1% | Jefferies | $145 | Buy | +104.9% | Reiterated | 28.10.25on TipRanks 12:20 | −2.3%next day +3.5% · 5 days −4.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering TransMedics Group
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $94.22 at a price of $83.45 (+12.9%); now: $97.44 at $70.78 (+37.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 13 | 12 | 8 | 5 | 4 |
| Buy | 7 | 6 | 5 | 8 | 13 | 13 |
| Hold | 6 | 8 | 6 | 7 | 5 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.30 (from $0.15 to $0.40). Last quarter: $0.44.
Sales
Next quarter’s sales estimate — $178M (from $170M to $188M). Last quarter: $190M.
Best top-analyst consensus in the sector · Healthcare
About TransMedics Group
- CEO: Waleed H. Hassanein
- Employees: 898
- 200 Minuteman Road, Andover, MA, 01810, US
- www.transmedics.com
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Data from the stock’s TipRanks forecast page, read 67 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗